Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wrong. Mark gets NO MONEY from the trading activity of ARYC (and never has). There is NO DILUTION.
Arrayit has been a public company only since 2008.
You’re welcome.
To believe Mark is sitting around playing with ARYC stock is absolutely absurd.
Totally agree. The case has been a drag on the company for far too long. In the beginning the Judge estimated the case would last just 18 months! So much for that. Taub caused so much grief. I think he is sneaky, greedy, and evil.
Lol. Their “damages expert” cannot decide cases. Judges do and NO MONEY judgment was ordered. Good grief.
Slow is too kind a word.
The SEC hates market manipulation and is taking the scoundrels on, one by one. Would you like to know what Andrew at the SEC told me during our nice, long conversation?
Ridiculous and wrong.
Contrary to what you keep posting, there was NO ORDER for ARYC to pay a dime to Taub. They have NOT proven damages. If they can PROVE damages, it will most likely settle out of court for nowhere near what Taub the crook is claiming. Getting involved with Taub was a horrible decision in the first place. He committed securities fraud while employed at Paine Webber and was barred for life from the securities business by the SEC.
The Judge said the defendants provided NO PROOF OF DAMAGES. What you posted is what the crooks were claiming through their "damages expert" and that was NOT AN ORDER OF THE COURT. How disgusting that you would post that.
"Plaintiffs did not receive the Products, which their damages expert estimated was worth $20,550,000. Pl.’s Ex. Y at 1, ECF No. 171. Further, Plaintiff Zalcberg did not receive the 5 million shares, which Plaintiffs damages expert estimated was worth $780,000. Id."
Everyone knows there is no proof, so what's your point. We all know why the stock is sitting where it is. Duh. Why not PROVE that there's nothing going on there!
Why would they be worthless? ARYC is already billing several millions of dollars a month JUST for the allergy/asthma testing and those tests are covered by Medicare, Medicaid, and other health insurers. Adding the COVID-19 revenue is just more icing on the cake, and they are currently conducting those tests for their existing client base. Emergency authorization for their COVID-19 test and the FDA's approval of an in-home test kit would add a big fat pile of cherries and icing on the ARYC cake.
Das right.
If you don't believe any of this, that's AOK with me!
OK. Will do.
lolol.
Nobody cares? Speak for yourself.
He asked for the SCIENCE, and I showed him the SCIENCE. Dr. Schena's SCIENCE is used throughout the world and his SCIENCE is testing for COVID-19, allergies, and asthma, and more RIGHT NOW. The SCIENCE is something EVERYONE should care about.
Too bad you're not interested in Dr. Schena's CONTRIBUTION OF SCIENCE to the universe. Instead, let's just make it ALL ABOUT the share price and make every effort to destroy the share price, let alone making disgusting comments about Dr. Schena, Rene, and the company as a whole.
It's sickening.
Here ya go; it's deep, I know: Dr. Mark Schena - Science.
"During his studies at Berkeley, Schena showed that changes in citrate synthase expression cause changes in flux through the citric acid cycle. This work showed the importance of rate limiting steps in enzymatic pathways. As a graduate student at UCSF, Schena discovered the evolutionary conservation of cellular mechanisms across eukaryotic evolution by demonstrating the conservation of mammalian glucocorticoid receptor function in the yeast Saccharomyces cerevisiae. At Stanford, Schena pioneered a new field of science (microarray technology) as the first author on the Stanford team publication in the journal Science demonstrating that complementary DNA molecules immobilized on glass could be used to measure gene expression in the flowering plant Arabidopsis thaliana. The modern microarray industry and solid-phase DNA sequencing industry have drawn heavily from the 1995 Science paper. More than 42,000 peer-reviewed microarray publications have appeared in the scientific literature since 1995.
Schena has written four books on microarrays, including the first textbook on the subject, and has been featured by journalists in interviews covered by the print media, radio and television. Schena has pioneered an extensive line of microarray products and services at Arrayit. Schena is the inventor of Variation Identification Platform (VIP) technology, which is capable of genotyping up to 80,000 patients in a single microarray test.[11] Schena has taken an active role in healthcare reform in the United States by promoting the importance of technical innovation as a means of improving the quality and accessibility of healthcare and controlling its cost. Schena is considered the foremost authority on microarray technology, referred to as the "Father of Microarray Technology".
In 2001, Schena was featured on the Nova television documentary "Cracking the Code of Life", a two-hour special hosted by ABC News Nightline correspondent Robert Krulwich.[14] Schena first introduced microarrays as pre-symptomatic diagnostic tools on the 2001 Nova program. Schena holds the first and second positions on "The Microarray Family Tree", a historiograph of 13 influential papers published in the microarray field, written by Eugene Garfield.[15] The Scientist also credited Schena with creating the first array.[16] Schena was proclaimed the "Father of Microarrays" in an article written by Lloyd Dunlap, contributing editor of Drug Discovery News, in an account of Schena's pioneering work to decipher Parkinson's disease.[17] Schena and Rene Schena reside in Los Altos, California.
Thanks for sharing. Not sure why you were shocked and amazed though. This is what Arrayit DOES and the requests come from doctors and clinics. Last we knew, which was a week or so ago, they had 50,000 requests for Covid-19 tests.
Catty, we don’t know the status of the COVID-19 test that they submitted to the feds yet. So we wait. Would love to know if they have been testing ARYC’s already established clients, which I believe they’re allowed to do prior to official emergency authorization by the FDA. That wouldn’t surprise me at all, and that alone would keep them scrambling and crazy-busy trying to fit it in with their already booming allergy testing business, among other things.
Stay well...
Das right.
Duh. In order to have a pump and dump, there has to be a pump and dump. lol.
See Dick and Jane. They live in a very nice house with their mommy and daddy and little doggie (first grade primer).
Good answer. :))
Notice: The US Government, DOES DEAL with Arrayit and has for MANY YEARS. I am talking about the FDA, USDA, DOD, National Institutes of Health, U.S. Army, the Department of Veterans Affairs, the Centers for Disease Control and Prevention (CDC), and there could be more.
Want proof??? Look it up.
No one cares. No one ever said Walgreens sold Pinnertest. And Arrayit doesn’t even make what you inquired about in your email. What you should be interested in is Walgreens health care clinics and what ARYC may be bringing to the table. This has been explained to you several times. Your email is of no value whatsoever. Zippo.
Thanks PSA! Hmmmm..something’s afoot?.
:))
lol. "Arrayit" is all over that company. Just visit the website and R-E-A-D all about it.
Hi Jerry. Looks like a private biotech with research funding from the EU, and located in the Czech Republic:
ESSENCE LINE is a biotech company with its own research & development, founded in 2002. Our team includes professionals with analytical and technological background focusing on market-oriented development, products and services primarily in the areas related to REACH, genotoxicity, endocrine disruptors, cytotoxicity, DNA diagnostics and other biochemical analysis. Accompanied with complete training and technical documentation, we deliver and master advanced micro fluctuation assays (genotoxicity, endocrine disruptors, cytotoxicity), DNA Diagnostics (RT-PCR, micro/nanoarrays), technology transfers and supplies of turnkey projects.
Over the last decade, we have established ourselves in leading academic institutions and private pharma and biotech companies both in the Czech Republic and worldwide delivering our products and services on a turnkey level. ESSENCE LINE as SMEs has participated in EU-supported research projects focused on developing new diagnostic tools and advanced laboratory facilities especially focusing on health care and environment.
Microarrays
Our team has been specialized to protein and DNA microarrays for over 10 years. In cooperation with Arrayit and different research insitutes (Masaryk University, Verona University, Ceitec, Biocev, ICT Prague, Charles University etc.), we have been providing unparallel custom microarray design and production, their analyses and bioinformatic interpretation, moreover, deliveries from key components (microarrayers, scanners, hybstations etc.) to entire Biochip labs (Biochip platforms) .
https://www.essenceline.cz/microarrays/
OK, now everyone is a disciple begging for 4 stupid cents. I guess there's nothing left to say. Brilliant deduction though.
lolol.
Arrayit all the way!
"Over the past months, ARYC has continued pumping the share price to try and drive the price from 2 cents to 4 cents on a continual basis."
I know what a P&D is and that is NOT what is going on. ARYC is not that kind of company. NO pumps and NO dumps. Plus, don't forget the stock market in general has NO CLUE (yet) about what we have here.
Weirdness.
Do you need everything spelled out for you??? If they didn't have a bona fide test for COVID-19, then why would they post step-by-step instructions for physicians on how to conduct the test?
Everyone KNOWS the share price has fallen, so why do you have to keep repeating it? Beat up share prices make me happy.
Yes sir, SD, absolutely agree. It's just a matter of time before we hear what ARYC has been up to over the past several weeks.
Looks like sellers are few and far between and not selling into the cheap bids. I think ARYC wants to BURST!
That company is NOT approved here and is only sending "samples" to countries outside of the US. They have submitted their test to the FDA for for "possible clearance" for emergency authorization, just like ARRAYIT has. But thanks for trying to mislead.
https://www.medicaldevice-network.com/news/biomerica-finger-prick-covid-19/
What is interesting is the fact that Walgreens’ clinical partner is Labcorp but their coronavirus test uses goo from noses and not drops of blood from a finger prick, so this could indeed be Arrayit’s test. We shall see...
I'm laughing too. Thank you for all your brilliant contributions to this board.
lol. I knew it would be a really stupid food fight, but we're HEADED NORTH in a very big way, and it may take some time, but it will be well worth the wait. Need to see some BIG volume days for the magic to happen.
:)
Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains
July 02, 2018 05:30 ET | Source: Arrayit Corporation
Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
Arrayit allergy testing is particularly suitable for large retail chains because convenient finger stick sampling allows customers to integrate a physician-ordered allergy test into their real-time shopping experience. The test results, together with patient symptoms and medical history, enable in-store doctors to make personalized medical recommendations about allergy and asthma treatments and medicines, which are also conveniently provided by the retailer. The retail chain, which reports revenues exceeding $50,000,000,000 ($50 billion US dollars) annually, has more than 2,000 locations nationwide.
Dear Valued Customer, We received more than 50,000 requests for our
finger stick blood test for SARS-CoV-2, the virus that causes
coronavirus disease 2019 (COVID-19). Our team is coordinating with
local, state and federal agencies and with our distributors to make this
test available to as many patients as possible on an expedited timeline.
Please consult our website and press releases for updates.
Best regards,
Arrayit Corporation